

THOMPSON STREET

C A P I T A L P A R T N E R S

THOMPSON STREET CAPITAL PARTNERS PORTFOLIO COMPANY BIORECLAMATIONIVT ACQUIRES TRANSCCELL SCIENCE

ST. LOUIS (February 15, 2017) – Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis together with Arsenal Capital Partners, a New York-based private equity firm, announced that their portfolio company BioreclamationIVT has acquired TransCell Science (TCS), a privately held contract research organization (CRO) headquartered in New York City. TCS specializes in the use of primary cells for phenotypic screening assays. Terms of the transaction were not disclosed.

TCS (www.transcellscience.com) provides preclinical drug development assays as well as primary human cell isolation from tissue explants. The Company has been a trusted research partner for top 10 pharmaceutical and biotech companies, multinational personal care products and cosmetics brand providers, leading academic institutions and the National Institutes of Health.

###